Find Clinical Trials & Studies

Visit the Research & Education Institute

PF-06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

I'm Interested!

Please call
1-866-373-1464

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

Sex: Male
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Prostate

Study Purpose

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

Principal Investigator
Jason Brown MD PhD

Department/Division
Cancer (Genitourinary)

UH IRB: STUDY20250717
StudyID: PFIZ2825
ClinicalTrials.gov: NCT07028853

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464